Thermo Fisher Scientific Inc. $TMO Shares Sold by Northern Trust Corp

Key Points

• Northern Trust Corp reduced its stake in Thermo Fisher Scientific Inc. by 0.7%, owning approximately 3.88 million shares valued at around $1.93 billion after the sale.
• Analyst ratings have fluctuated, with HSBC Global Research downgrading TMO from a "strong-buy" to a "hold," while the average target price is now $593.00 with a consensus rating of "Moderate Buy."
• Thermo Fisher Scientific announced a quarterly dividend of $0.43 per share, reflecting an annualized yield of 0.4%.

Northern Trust Corp decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,882,819 shares of the medical research company's stock after selling 27,196 shares during the period. Northern Trust Corp owned approximately 1.03% of Thermo Fisher Scientific worth $1,932,091,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in TMO. Brighton Jones LLC grew its holdings in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after buying an additional 20 shares during the period. Bank Pictet & Cie Europe AG raised its holdings in Thermo Fisher Scientific by 0.3% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock worth $79,677,000 after purchasing an additional 461 shares during the period. First Trust Advisors LP raised its holdings in Thermo Fisher Scientific by 17.4% in the 4th quarter. First Trust Advisors LP now owns 36,602 shares of the medical research company's stock worth $19,042,000 after purchasing an additional 5,438 shares during the period. Finally, Curi RMB Capital LLC increased its stake in Thermo Fisher Scientific by 2.4% in the 4th quarter. Curi RMB Capital LLC now owns 17,901 shares of the medical research company's stock worth $9,313,000 after buying an additional 418 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. UBS Group lifted their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective on the stock in a report on Friday, July 11th. William Blair assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday. They set an "outperform" rating for the company. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Finally, Barclays increased their price target on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research note on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $593.00.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total transaction of $4,518,200.00. Following the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at $52,037,916.68. This trade represents a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,896 shares of company stock worth $8,593,838 in the last three months. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

TMO stock traded down $11.3820 during trading on Thursday, reaching $483.4280. 1,360,628 shares of the company were exchanged, compared to its average volume of 2,488,796. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The company has a market cap of $182.55 billion, a P/E ratio of 27.96, a PEG ratio of 2.66 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The stock's 50 day moving average price is $439.69 and its 200 day moving average price is $458.78.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the prior year, the firm earned $5.37 earnings per share. The company's revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.